Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

NCT06229041 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT06229041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06229041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 3
Overall status
Recruiting
Start date
March 29, 2023
Completion date
October 1, 2029
Enrollment
472 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer